Our Story
Closing the gap between science and care
Closing the gap between science and care
Evident Mental Health was founded around a simple observation: modern science has transformed what we know about treating psychosis, but too few people benefit from these advances.
Over the past several decades, researchers around the world have developed better medications, better ways of monitoring recovery, and better models of care. Yet many individuals living with psychosis continue to receive treatment that does not fully reflect what is known to work.
For patients and families, this often means years of unnecessary symptoms, repeated hospitalizations, difficult side effects, and missed opportunities for recovery—not because better care does not exist, but because it is difficult to access.
Why We Believe This Matters
Throughout our clinical, academic, and research work, we have seen the same pattern repeatedly: the greatest challenge is often not discovering better treatments—it is making sure people actually receive them. Too often, effective treatments are introduced late, important side effects are not systematically monitored, progress is difficult to measure, and families are left without the guidance they need. We believe patients deserve better.
A Different Model of Care
Specialized expertise in psychosis
Evidence-based psychopharmacology
Measurement-based care
Structured monitoring
Collaboration with families and providers
A recovery-oriented and trauma-informed philosophy
About Our Founder
Jose M. Rubio, MD, PhD — Founder & Medical Director
Jose M. Rubio, MD, PhD
Founder & Medical Director
Dr. Rubio is a board-certified psychiatrist specializing in the treatment of psychosis and schizophrenia. He combines years of clinical experience caring for individuals with severe mental illness with an active research program focused on improving outcomes for people living with psychotic disorders.
His work has been recognized by organizations including the Schizophrenia International Research Society and the American College of Neuropsychopharmacology, and his research has been supported by the National Institutes of Health.
His research focuses on personalized psychiatry, treatment resistance, relapse prevention, the development of novel treatments, and understanding how to bring evidence-based care into routine clinical practice.
